XNAS · Healthcare · Biotechnology
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | Q2 2026 | -1.59 | -1.52 | +4.40% | $0 | ✅ Beat | +1.30% | +0.16% | — |
| 2026-05-07 | Q1 2026 | -1.35 | -1.69 | -25.19% | $0 | ❌ Miss | -0.26% | +10.26% | -10.01% |
| 2026-02-26 |
| Q4 2025 |
| -1.30 |
| -1.39 |
| -6.92% |
| $0 |
| ❌ Miss |
| +0.31% |
| -8.26% |
| -8.24% |
| 2025-11-05 | Q3 2025 | -1.16 | -1.26 | -8.62% | $0 | ❌ Miss | — | — | — |
| 2025-08-05 | Q2 2025 | -0.70 | -1.20 | -71.43% | $0 | ❌ Miss | -1.56% | +2.42% | +6.10% |
| 2025-02-26 | Q4 2024 | -0.73 | -0.72 | +1.37% | $0 | ✅ Beat | +5.91% | +7.89% | -4.11% |
| 2024-11-07 | Q3 2024 | -0.64 | -0.85 | -32.81% | $0 | ❌ Miss | -1.94% | -0.08% | -3.12% |
| 2024-03-20 | Q4 2023 | -0.51 | -0.58 | -13.73% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.